Frontier Pharma Pancreatic Cancer - Aarkstore.com

1
Frontier Pharma Pancreatic Cancer - Aarkstore.com
Category Pharmaceuticals and Healthcare
2

• Summary  Pancreatic cancer is the 12th most
  common cancer globally, and the fourth most
  fatal, with a mortality rate of 10.9 deaths per
  100,000 people per year. The poor prognosis of
  pancreatic cancer patients has highlighted a
  significant need for new and improved approaches
  to treatment, which is not being met by the
  current market.
• A highly active pancreatic cancer pipeline
  contains an array of products with varying
  molecule types and mechanisms of action, which
  provides a striking contrast to the current,
  chemotherapy dominated, market. Within the
  pipeline, there are 185 products that act on a
  first-in-class molecular target, representing 52
  of the total pancreatic cancer pipeline products
  that have a disclosed molecular target. A
  drastically different pipeline and market
  composition implies that the approach to
  pancreatic cancer treatment is changing and
  first-in-class innovation is playing a
  significant role in this.
•  Scope- Gemcitabine based regimens continue to
  dominate the market, which has seen few new
  entrants over the past decade. The continued
  reliance on generic chemotherapies is one reason
  why the prognosis has shown little
  improvement. - What survival benefits do current
  therapies provide? - What are the current unmet
  needs that the pipeline needs to address?

3

• Table of Content
• 1 Table of Contents 2 1.1 List of Tables
  3 1.2 List of Figures 3 2 Executive Summary
  4 2.1 Large and Diverse Pipeline Contrasts the
  Limited Market 4 2.2 Pancreatic Cancer Shows
  High Levels of First-in-Class Innovation 4 2.3
  High Deal Activity Reflects Dynamic Pipeline 4 3
  The Case for Innovation 5 3.1 Growing
  Opportunities for Biologic Products 6 3.2
  Diversification of Molecular Targets 6 3.3
  Innovative First-in-Class Product Developments
  Remain Attractive 6 3.4 Regulatory and
  Reimbursement Policy Shifts Favor First-in-Class
  Product Innovation 7 3.5 Sustained Innovation
  7 3.6 GBI Research Report Guidance 8 4 Clinical
  and Commercial Landscape 9 4.1 Disease Overview
  9 4.2 Disease Symptoms 9 4.3 Epidemiology 9

4
List Of Tables
Table 1 Tumor Node Metastasis Classification
13Table 2 Pancreatic Cancer Therapeutics, ECOG
Performance Status Scores and Description
15Table 3 Pancreatic Cancer Therapeutics,
Common Endpoints in Oncology Clinical Trials and
their Description 16 Table 4 Pancreatic Cancer
Therapeutics, Efficacy of Gemcitabine Monotherapy
16 Table 5 Pancreatic Cancer Therapeutics,
Efficacy of Gemcitabine Monotherapy 17 Table 6
Pancreatic Cancer Therapeutics, Efficacy of
Gemcitabine in Combination with Eloxatin 20 List
Of Figures  Figure 1 Innovation Trends in
Product Approvals 5 Figure 2 Sales Performance
of First-in-Class and Non-First-in-Class Product
Post Marketing Approval 7 Figure 3 Genetically
Altered Signaling Pathways in Pancreatic Cancer
12 Figure 4 Overview of Marketed Products in
Pancreatic Cancer 27 Figure 5 Overview of
Pipeline Products 30
Browse full report Or Sample Request
_at_ http//www.aarkstore.com/pharmaceuticals-healthc
are/127902/frontier-pharma-pancreatic-cancer-ident
ifying-and-commercializing-first-in-class-innovati
on
5

• Opioids Overview to 2021 - An Assessment of Pain
  Management and Dependence
• Frontier Pharma Innovative Licensing
  Opportunities in Non-Hodgkin Lymphoma
• United States Vitamin A Industry 2015 Market
  Research Report
• Europe Vitamin A Industry 2015 Market Research
  Report
• Japan Vitamin A Industry 2015 Market Research
  Report

Related Reports
6
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
7
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953